Results 31 to 40 of about 12,413,959 (307)

Utilization evaluation of factor concentration and frequencyof bleeds among patients with haemophilia "A" and haemophilia "B" in northwest Iran [PDF]

Journal of Analytical Research in Clinical Medicine, 2013
Background Haemophilia A and B are X-linked bleeding disorders which result in decreased blood levels of coagulants. According to some studies, Hemophilia Severity Score (HSS) is higher in severe Haemophilia A(HA) than in severe Haemophilia B(HB ...
Roya Dolatkhah, Morteza Ghojazadeh, Iraj Asvadi Kermani, Zohreh Sanaat, Nasrin Tavassoli, Mehri Gholchin   +5 more
doaj   +1 more source

rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires

Haemophilia, 2021
Recurrent bleeding in severe haemophilia B causes painful hemarthroses and reduces capacity for physical activity. Recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis results in low annualised bleeding rates, with the potential to improve ...
J. Astermark, C. Hermans, M. Ezzalfani, S. Aballéa, E. Santagostino, Z. Hakimi, J. Nazir   +6 more
semanticscholar   +1 more source

Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery

Haemophilia, 2021
Recombinant factor IX fusion protein concentrate (rFIXFc) is increasingly used for prophylaxis in people with haemophilia B (PWHB), but experience in the perioperative setting is limited.
Mairead O'Donovan, E. Singleton, Sheila Roche, M. McGowan, Julie Benson, C. Bergin, R. Bird, M. Byrne, C. Duggan, R. Gilmore, K. Ryan, A. Dougall, J. O’Donnell, N. O'Connell   +13 more
semanticscholar   +1 more source

Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study

Haemophilia, 2021
Data on outcome in persons with haemophilia B (PwHB) are limited and mainly extrapolated from studies of haemophilia A (HA).
K. Kihlberg, F. Baghaei, M. Bruzelius, E. Funding, P. Andrè Holme, R. Lassila, V. Nummi, S. Ranta, M. Osooli, E. Berntorp, J. Astermark   +10 more
semanticscholar   +1 more source

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Molecular Profiling of FIX (FACTOR 9) Gene of Hemophilia B in Karnataka

BLDE University Journal of Health Sciences, 2020
Introduction: Haemophilia is one of the “Bleeder Disorder” that causes abnormal bleeding or poor blood clotting. It occurs due to the defect in the clotting factors even in their functions and in some cases structures are altered.
Sujayendra Kulkarni, Rajat Hegde, Smita Hegde, Suyamindra Kulkarni, Sanjeev Kolagi, Pramod Gai, Rudragouda Bulagouda   +6 more
doaj   +1 more source

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

Haemophilia, 2020
Recombinant factor IX Fc fusion protein (rFIXFc) has demonstrated efficacy for treatment of haemophilia B in the Phase 3 B‐LONG and Kids B‐LONG studies. However, long‐term rFIXFc safety and efficacy data have not yet been reported.
K. J. Pasi, K. Fischer, M. Ragni, R. Kulkarni, M. Ozelo, J. Mahlangu, A. Shapiro, S. P'ng, H. Chambost, B. Nolan, Carolyn M Bennett, T. Matsushita, B. Winding, J. Fruebis, Huixing Yuan, D. Rudin, J. Oldenburg   +16 more
semanticscholar   +1 more source

Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo. [PDF]

PLoS ONE, 2017
Canine models of severe haemophilia resemble their human equivalents both regarding clinical bleeding phenotype and response to treatment. Therefore pre-clinical studies in haemophilia dogs have allowed researchers to make valuable translational ...
Daniel Elenius Madsen, Timothy C Nichols, Elizabeth P Merricks, Emily K Waters, Bo Wiinberg   +4 more
doaj   +1 more source

Safety, Efficacy and Treatment Patterns of rIX‐FP in Previously Untreated Paediatric Haemophilia B Patients: A Retrospective Chart Review in Japan [PDF]

Haemophilia, EarlyView.
Abstract Background Limited real‐world data exist on recombinant fusion protein‐linking coagulation factor IX (FIX) with albumin (rIX‐FP) in paediatric previously untreated patients (PUPs) with haemophilia B, particularly in infants. Aims To evaluate the treatment patterns, safety and efficacy of rIX‐FP in paediatric PUPs in Japan.
Keiji Nogami, Chiai Nagae, Masatoshi Yono, Naoki Terasaka   +3 more
openalex   +2 more sources

Haemophilia B

JMS SKIMS, 2016
Haemophilia is a group of inherited blood disorders in which blood does not clot properly. Bleeding disorders are due to defect in blood vessels, the coagulation mechanism or the blood platelets. Blood coagulation mechanism is a process which transforms blood from a liquid into solid and involves different clotting factors that generates fibrin fibers ...
Sabita Yograj, Neena Sharma
openaire   +2 more sources